Intech Investment Management LLC Sells 10,114 Shares of TransMedics Group, Inc. $TMDX

Intech Investment Management LLC reduced its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 34.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,913 shares of the company’s stock after selling 10,114 shares during the quarter. Intech Investment Management LLC’s holdings in TransMedics Group were worth $2,301,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of TMDX. Royal Bank of Canada raised its holdings in TransMedics Group by 47.9% in the 1st quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock valued at $1,788,000 after acquiring an additional 8,604 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in TransMedics Group by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock valued at $1,314,000 after acquiring an additional 868 shares during the period. Goldman Sachs Group Inc. raised its holdings in TransMedics Group by 20.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after acquiring an additional 86,721 shares during the period. Russell Investments Group Ltd. raised its holdings in TransMedics Group by 13.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock valued at $1,059,000 after acquiring an additional 938 shares during the period. Finally, M&T Bank Corp bought a new position in TransMedics Group in the 2nd quarter valued at about $209,000. 99.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

TMDX has been the topic of several research analyst reports. JPMorgan Chase & Co. increased their price target on shares of TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. TD Cowen lowered their price target on shares of TransMedics Group from $190.00 to $120.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. UBS Group reissued a “hold” rating on shares of TransMedics Group in a report on Tuesday, May 26th. Stifel Nicolaus lowered their price target on shares of TransMedics Group from $85.00 to $75.00 and set a “hold” rating on the stock in a report on Tuesday, May 26th. Finally, Oppenheimer cut shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 6th. Six research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $134.00.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX opened at $69.69 on Thursday. The company’s 50 day moving average price is $90.24 and its two-hundred day moving average price is $117.59. TransMedics Group, Inc. has a 12-month low of $60.10 and a 12-month high of $156.00. The firm has a market cap of $2.41 billion, a PE ratio of 15.84 and a beta of 1.91. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The business had revenue of $173.93 million for the quarter, compared to analyst estimates of $174.44 million. During the same quarter in the previous year, the company earned $0.70 EPS. The business’s revenue for the quarter was up 21.2% on a year-over-year basis. Equities research analysts predict that TransMedics Group, Inc. will post 1.98 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.